Providing Our Partner With Solutions In Titer, Host Cell Protein, And Scalability

In this case study, we successfully developed a late-stage–ready manufacturing process by creating a new clonal recombinant cell line and implementing rigorous control over post-translational modifications. Throughout development, we ensured alignment with the original Phase 1 quality target product profile (QTPP), preserving critical product attributes while enhancing process robustness and scalability.

By leveraging expertise across a global network and executing a streamlined, rapid technology transfer, we enabled a highly data-driven approach to clone selection and process optimization. This integrated strategy accelerated timelines, improved consistency, and supported confident decision-making at each stage of development.

Download the asset below to explore the full approach, key insights, and outcomes in greater detail.